Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies

LONDON, ONTARIO–(Marketwired – Sept. 10, 2015) – Sernova Corp. (TSX VENTURE:SVA)(FRANKFURT:PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as …

[Read the full article here]

Comments are closed.